Literature DB >> 14576502

Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas.

F Charles Brunicardi1, Azmi Atiya, Stefan Moldovan, Timothy C Lee, Shawn P Fagan, Robert M Kleinman, Thomas E Adrian, David H Coy, John H Walsh, William E Fisher.   

Abstract

OBJECTIVES: Five distinct somatostatin receptors (SSTRs) have been cloned, characterized, and designated SSTRs 1-5. The role of these receptors in B-cell signaling has not been well characterized.
METHODS: In the current study, the isolated perfused human pancreas model was used to determine the specific effect of 4 different somatostatin receptor agonists on insulin secretion.
CONCLUSION: We demonstrated that the SSTR 2 agonist and octreotide significantly suppressed insulin secretion. Furthermore, even during the immunoneutralization of endogenous intrapancreatic somatostatin, the SSTR 2 agonist was able to reverse the effect of somatostatin immunoneutralization by suppressing insulin secretion. These results demonstrate that activation of SSTR 2 suppresses insulin secretion in the isolated perfused human pancreas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576502     DOI: 10.1097/00006676-200311000-00019

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

2.  Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

3.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

4.  Pancreatic network control of glucagon secretion and counterregulation.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

5.  Glucagon responses to exercise-induced hypoglycaemia are improved by somatostatin receptor type 2 antagonism in a rat model of diabetes.

Authors:  Erwan Leclair; Richard T Liggins; Ashley J Peckett; Trevor Teich; David H Coy; Mladen Vranic; Michael C Riddell
Journal:  Diabetologia       Date:  2016-04-13       Impact factor: 10.122

6.  SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.

Authors:  Balrik Kailey; Martijn van de Bunt; Stephen Cheley; Paul R Johnson; Patrick E MacDonald; Anna L Gloyn; Patrik Rorsman; Matthias Braun
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-08-28       Impact factor: 4.310

7.  A Broad Spectrum Chemokine Inhibitor Prevents Preterm Labor but Not Microbial Invasion of the Amniotic Cavity or Neonatal Morbidity in a Non-human Primate Model.

Authors:  Michelle Coleman; Austyn Orvis; Tsung-Yen Wu; Matthew Dacanay; Sean Merillat; Jason Ogle; Audrey Baldessari; Nicole M Kretzer; Jeff Munson; Adam J Boros-Rausch; Oksana Shynlova; Stephen Lye; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

8.  A Broad-Spectrum Chemokine Inhibitor Blocks Inflammation-Induced Myometrial Myocyte-Macrophage Crosstalk and Myometrial Contraction.

Authors:  Adam Boros-Rausch; Oksana Shynlova; Stephen James Lye
Journal:  Cells       Date:  2021-12-31       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.